Want to join the conversation?
Leerink Partners analyst Jason Gerberry asked for an update on the approval of 505(b)(2) products. $ENDP said it has two 505(b)(2) products approved and it is working with FDA to have the unapproved sources come off the market. The company said the benefit of having the unapproved sources exit the market will be realized in 2017.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th